Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
1.4 - 1.5 mg per m² of body surface area (BSA)
From 1.4 To 1.5 mg per m² of body surface area (BSA) once every 7 day(s)
The drug is administered intravenously at weekly intervals. The recommended dose is 1.4 to 1.5 mg/m² up to a maximum weekly dose of 2 mg.